Kling Biotherapeutics (NASDAQ: KLNG), a biotech firm that specialises in antibody-based drugs from its B-cell platform, announced on Tuesday that it has appointed Dr Stefano Gullà as Chief Scientific Officer.

Dr Gullà has more than 15 experience in biotherapeutics amd previously held key roles at Pfizer, Agenus, Flagship and RVAC, leading the development of pioneering immuno-oncology and autoimmunity therapeutics.

Michael Koslowski, Kling Bio's CEO, anticipates Dr Gullà's leadership to propel the company toward becoming a global drug discovery leader. Dr Gullà expresses excitement about scaling Kling's proven platform for cancer and infectious diseases.

Apart from his industry success, Dr Gullà founded Abcuro in 2016, raising over USD60m for cancer and autoimmune therapeutics. His academic background includes a PhD from Northeastern University and postdoctoral training at MIT.

Based in Amsterdam, Kling's 's pipeline includes KBA1412, a Phase 1 CD9 antibody for oncology. Its proprietary platforms, Kling-Select and Kling-Evolve, leverage B-cell technology for target discovery and antibody identification.